Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Biodesix Inc's Business Segments
Biodesix Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Diagnostic Tests
Total Revenue
$ 27
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Diagnostic Tests0%
- Development Services17.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Diagnostic Tests | $ 48 | - |
| Development Services | $ 5 | 17.8% |
Revenue by Product & Service Category - FY
- Diagnostic Tests87.2%
- Development Services12.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Diagnostic Tests | $ 22 | 87.2% |
| Development Services | $ 3 | 12.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Diagnostic Tests0%
- Development Services17.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Diagnostic Tests | $ 48 | - |
| Development Services | $ 5 | 17.8% |
Description of Biodesix Inc
Biodesix Inc. is a leading molecular diagnostics company that focuses on the development and commercialization of innovative blood-based tests for personalized medicine. The company was founded in 2005 and is headquartered in Boulder, Colorado, USA.
Biodesix is dedicated to enhancing patient outcomes through the delivery of high-quality and actionable diagnostic information. They aim to provide clinicians with valuable insights that help guide treatment decisions, improve patient outcomes, and reduce healthcare costs.
The company's core technology revolves around their proprietary blood-based molecular diagnostics platform, known as the GeneStrat® test. This test analyzes specific gene mutations and alterations in the DNA of patients' tumors, allowing for a more precise and personalized approach to cancer treatment. It helps identify targeted therapies that are most likely to be effective for individual patients, as well as monitors the effectiveness of treatment and identifies potential resistance mechanisms that may arise during therapy.
Biodesix has also developed other blood-based tests and assays, including VeriStrat® and Nodify®. VeriStrat is a serum protein test that provides valuable prognostic information for patients with lung cancer. It helps predict patient survival, enabling clinicians to make more informed treatment decisions. Nodify is a lung nodule risk assessment test that helps prioritize the management of lung nodules found in high-risk individuals.
In addition to their diagnostic tests, Biodesix has a strong focus on research and development. They continuously strive to expand their portfolio of innovative products by investing in cutting-edge technologies and collaborating with leading academic institutions, research organizations, and pharmaceutical companies.
Biodesix has established a strong presence in the healthcare market, with their tests being utilized by physicians, oncologists, and healthcare professionals in various clinical settings. They have successfully partnered with numerous pharmaceutical companies to conduct clinical trials and provide companion diagnostics for their targeted therapies.
The company has received several important certifications and accreditations, including ISO 13485:2016 certification for their quality management system, as well as the Clinical Laboratory Improvement Amendments (CLIA) certification, ensuring the accuracy and reliability of their laboratory operations.
Biodesix is committed to advancing the field of personalized medicine and improving patient care. By offering innovative blood-based tests that provide clinically actionable information, they are revolutionizing the way cancer is detected, diagnosed, and treated.
Biodesix is dedicated to enhancing patient outcomes through the delivery of high-quality and actionable diagnostic information. They aim to provide clinicians with valuable insights that help guide treatment decisions, improve patient outcomes, and reduce healthcare costs.
The company's core technology revolves around their proprietary blood-based molecular diagnostics platform, known as the GeneStrat® test. This test analyzes specific gene mutations and alterations in the DNA of patients' tumors, allowing for a more precise and personalized approach to cancer treatment. It helps identify targeted therapies that are most likely to be effective for individual patients, as well as monitors the effectiveness of treatment and identifies potential resistance mechanisms that may arise during therapy.
Biodesix has also developed other blood-based tests and assays, including VeriStrat® and Nodify®. VeriStrat is a serum protein test that provides valuable prognostic information for patients with lung cancer. It helps predict patient survival, enabling clinicians to make more informed treatment decisions. Nodify is a lung nodule risk assessment test that helps prioritize the management of lung nodules found in high-risk individuals.
In addition to their diagnostic tests, Biodesix has a strong focus on research and development. They continuously strive to expand their portfolio of innovative products by investing in cutting-edge technologies and collaborating with leading academic institutions, research organizations, and pharmaceutical companies.
Biodesix has established a strong presence in the healthcare market, with their tests being utilized by physicians, oncologists, and healthcare professionals in various clinical settings. They have successfully partnered with numerous pharmaceutical companies to conduct clinical trials and provide companion diagnostics for their targeted therapies.
The company has received several important certifications and accreditations, including ISO 13485:2016 certification for their quality management system, as well as the Clinical Laboratory Improvement Amendments (CLIA) certification, ensuring the accuracy and reliability of their laboratory operations.
Biodesix is committed to advancing the field of personalized medicine and improving patient care. By offering innovative blood-based tests that provide clinically actionable information, they are revolutionizing the way cancer is detected, diagnosed, and treated.
Biodesix Inc. is a biotechnology company specializing in the development and commercialization of diagnostics and precision medicine solutions, primarily aiming to improve outcomes for patients with lung disease, particularly lung cancer. The company focuses on leveraging its proprietary diagnostic technologies to provide tailored insights that can guide treatment decisions. Here is a detailed overview of the segments, products, and services offered by Biodesix:
Segments
1. Cancer Diagnostics:
- This segment primarily deals with the development of tests that assist in the diagnosis and management of lung cancer. Biodesix aims to provide information that can inform treatment paths and improve patient outcomes through precise testing.
2. Companion Diagnostics:
- Biodesix offers services that align with pharmaceutical research and development, specifically tests that can help identify patients who would benefit from specific drug therapies, thus supporting the personalized medicine framework.
3. Biomarker Development:
- The company focuses on the research and identification of biomarkers relevant to lung cancer. This involves both proprietary and collaborative efforts to discover and validate biomarkers that can assist in diagnostics.
Products
1. GeneStrat:
- This is a liquid biopsy test designed to detect actionable mutations in the genes commonly associated with non-small cell lung cancer (NSCLC). It analyzes cfDNA (circulating free DNA) from a blood sample and provides insights on genetic mutations that may inform targeted therapies.
2. Vermillion:
- Another diagnostic test that provides important genomic data for lung cancer patients, offering insights into treatment options and prognosis. Vermillion focuses on identifying a range of mutations and biological markers.
3. Bronchial Genomic Classifier:
- This product supports the differentiation between benign and malignant lung nodules in patients. It utilizes genomic profiling to help determine the likelihood that a lung nodule is cancerous, thereby aiding clinical decision-making.
4. COVID-19 Testing:
- In response to the pandemic, Biodesix also developed and offered tests related to COVID-19, although their primary focus remains on lung cancer diagnostics.
Services
1. Clinical Support:
- Biodesix provides services that support healthcare providers in interpreting diagnostic results and integrating them into patient care. This includes educating clinicians about test results and their implications for treatment strategies.
2. Biomarker Optimization:
- The company engages in optimizing and validating biomarkers to help develop new diagnostic tests and improve existing ones. This involves extensive research and clinical studies to ensure reliability and accuracy.
3. Partnerships in Precision Medicine:
- Biodesix collaborates with pharmaceutical companies, research institutions, and healthcare organizations to further the development of precision medicine strategies. This partnership often involves providing diagnostic tools that align with drug development and patient treatment protocols.
4. Laboratory Services:
- Biodesix operates a state-of-the-art laboratory where comprehensive testing is performed. This includes rigorous quality control and assurance processes to maintain high standards of accuracy and reliability in diagnostics.
Future Initiatives
Biodesix continues to seek new opportunities to expand its product offerings and enhance its diagnostic capabilities. This encompasses ongoing research and development to identify new biomarkers and improve upon existing tests. The companys commitment to personalized medicine drives its mission to deliver accurate and timely insights that can lead to better patient outcomes in lung cancer treatment and beyond.
In summary, Biodesix Inc. offers an array of sophisticated diagnostic solutions and services centered on lung cancer, with an ongoing commitment to advancing precision medicine through research, innovation, and collaboration.
Segments
1. Cancer Diagnostics:
- This segment primarily deals with the development of tests that assist in the diagnosis and management of lung cancer. Biodesix aims to provide information that can inform treatment paths and improve patient outcomes through precise testing.
2. Companion Diagnostics:
- Biodesix offers services that align with pharmaceutical research and development, specifically tests that can help identify patients who would benefit from specific drug therapies, thus supporting the personalized medicine framework.
3. Biomarker Development:
- The company focuses on the research and identification of biomarkers relevant to lung cancer. This involves both proprietary and collaborative efforts to discover and validate biomarkers that can assist in diagnostics.
Products
1. GeneStrat:
- This is a liquid biopsy test designed to detect actionable mutations in the genes commonly associated with non-small cell lung cancer (NSCLC). It analyzes cfDNA (circulating free DNA) from a blood sample and provides insights on genetic mutations that may inform targeted therapies.
2. Vermillion:
- Another diagnostic test that provides important genomic data for lung cancer patients, offering insights into treatment options and prognosis. Vermillion focuses on identifying a range of mutations and biological markers.
3. Bronchial Genomic Classifier:
- This product supports the differentiation between benign and malignant lung nodules in patients. It utilizes genomic profiling to help determine the likelihood that a lung nodule is cancerous, thereby aiding clinical decision-making.
4. COVID-19 Testing:
- In response to the pandemic, Biodesix also developed and offered tests related to COVID-19, although their primary focus remains on lung cancer diagnostics.
Services
1. Clinical Support:
- Biodesix provides services that support healthcare providers in interpreting diagnostic results and integrating them into patient care. This includes educating clinicians about test results and their implications for treatment strategies.
2. Biomarker Optimization:
- The company engages in optimizing and validating biomarkers to help develop new diagnostic tests and improve existing ones. This involves extensive research and clinical studies to ensure reliability and accuracy.
3. Partnerships in Precision Medicine:
- Biodesix collaborates with pharmaceutical companies, research institutions, and healthcare organizations to further the development of precision medicine strategies. This partnership often involves providing diagnostic tools that align with drug development and patient treatment protocols.
4. Laboratory Services:
- Biodesix operates a state-of-the-art laboratory where comprehensive testing is performed. This includes rigorous quality control and assurance processes to maintain high standards of accuracy and reliability in diagnostics.
Future Initiatives
Biodesix continues to seek new opportunities to expand its product offerings and enhance its diagnostic capabilities. This encompasses ongoing research and development to identify new biomarkers and improve upon existing tests. The companys commitment to personalized medicine drives its mission to deliver accurate and timely insights that can lead to better patient outcomes in lung cancer treatment and beyond.
In summary, Biodesix Inc. offers an array of sophisticated diagnostic solutions and services centered on lung cancer, with an ongoing commitment to advancing precision medicine through research, innovation, and collaboration.